Announcement: Expanded evaluation agreement with the University of Barcelona

We are pleased to announce that our evaluation agreement has been expanded to a broader collaboration including additional modules targeting KRAS (Kirsten RAt Sarcoma) as possible drugs for treating cancer) with the University of Barcelona.

The University of Barcelona has an active research group working in this area and has been awarded a grant to further study the effects of the same lead series. ValiRx has entered into an expansion of the initial evaluation agreement (“Expanded Evaluation Agreement”) to continue to work alongside the recently funded Barcelona research team to build a broader understanding of the biological activity of the drug candidates.

Speaking about the expansion, ValiRx CEO Dr @Suzy Dilly said: “We are delighted to be able to provide a letter of industrial support for the grant application by the University of Barcelona and we very much look forward to reviewing the additional data generated by the team. The capability of this team in generating leads for assessment is truly impressive, and we’re pleased that we have set up this broader framework to allow us to assess new molecules efficiently if they emerge as suitable candidates for further development.”

Find out more about the news and what it means for ValiRx in Suzanne's interview with BRR Media below: